
Compounding Pharmacy Cited for Unlicensed Biologics
FDA sent a warning letter to Pharmaceutic Labs, LLC for deficiencies in producing sterile drugs.
FDA sent a
According to the warning letter, the company was producing biologic products without a biologics license and not under GMPs. FDA inspectors found that the company had not properly disinfecting aseptic processing areas. “Your firm failed to demonstrate through appropriate studies that your aseptic processing areas are able to provide adequate protection of the ISO 5 areas in which sterile products are processed. Therefore, your products may be produced in an environment that poses a significant contamination risk,” FDA stated in the letter. Other violations included failure to establish written procedures for the prevention of microbiological contamination, failure to establish an adequate cleaning and disinfecting system, failure to determine conformance specifications, and failure to establish laboratory controls.
FDA recommended that the company assess its facility design, procedures, personnel, processes, materials, and systems. “You should fully implement necessary corrections in order to ensure that the drug products produced by your firm conform to the basic quality standards regarding safety, identity, strength, quality, and purity,” FDA stated.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.